Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model.
OBJECTIVE
A novel PEGylated and heparinized magnetic iron oxide nano-platform (DNPH) was synthesized for simultaneous magnetic resonance imaging (MRI) and tumor targeting.


METHODS
Starch-coated magnetic iron oxide nanoparticles ("D") were crosslinked, aminated (DN) and then simultaneously PEGylated and heparinized with different feed ratios of PEG and heparin (DNPH1-4). DNPH products were characterized by Fourier transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM) and superconducting quantum interference device (SQUID). The magentic targeting of DNPH3, with appropriate amounts of conjugated PEG and heparin, in a mouse 9L-glioma subcutaneous tumor model was confirmed by magnetic resonance imaging (MRI)/electron spin resonance (ESR).


RESULTS
DNPH3 showed long circulating properties in vivo (half-life >8 h, more than 60-fold longer than that of parent D) and low reticuloendothelial system (RES) recognition in liver and spleen. Protamine, a model cationic protein, was efficiently loaded onto DNPH3 with a maximum loading content of 26.4 μg/mg Fe. Magnetic capture of DNPH3 in tumor site with optimized conditions (I.D. of 12 mg/kg, targeting time of 45 min) was up to 29.42 μg Fe/g tissue (12.26% I.D./g tissue).


CONCLUSIONS
DNPH3 showed the potential to be used as a platform for cationic proteins for simultaneous tumor targeting and imaging.
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnosis School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Jian
J
Zhang
Meong Cheol
MC
Shin
Victor C
VC
Yang
D000818:Animals; D016503:Drug Delivery Systems; D005290:Ferric Compounds / Q000737:chemistry* / Q000493:pharmacokinetics; D005910:Glioma / Q000175:diagnosis*; D006493:Heparin / Q000737:chemistry / Q000493:pharmacokinetics; D008279:Magnetic Resonance Imaging; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D053758:Nanoparticles / Q000737:chemistry / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry / Q000493:pharmacokinetics; D011479:Protamines / Q000008:administration & dosage
D005290:Ferric Compounds; D011479:Protamines; C000499:ferric oxide; D011092:Polyethylene Glycols; D006493:Heparin